BioXcel Therapeutics
BTAI
BTAI
85 hedge funds and large institutions have $140M invested in BioXcel Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
16% less capital invested
Capital invested by funds: $167M → $140M (-$27.2M)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Holders
85
Holding in Top 10
–
Calls
$2.56M
Puts
$933K
Top Buyers
| 1 | +$1.26M | |
| 2 | +$473K | |
| 3 | +$409K | |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$365K |
| 5 |
Morgan Stanley
New York
|
+$330K |
Top Sellers
| 1 | -$5.17M | |
| 2 | -$2.49M | |
| 3 | -$1.17M | |
| 4 |
Two Sigma Investments
New York
|
-$991K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$976K |